✦ LIBER ✦

Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine

✍ Scribed by Carlos Rodriguez-Galindo; Patrick Kelly; Michael Jeng; Gerald G. Presbury; Martha Rieman; Winfred Wang

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 121 KB
Volume: 69
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.10053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neuropsychologic deficits in children wi

Neuropsychologic deficits in children with Langerhans cell histiocytosis

✍ Whitsett, Stan F.; Kneppers, Kirstie; Coppes, Max J.; Egeler, R. Maarten 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

Background. Manifestations of Langerhans cell histiocytosis (LCH) in children range from only a rash, to bony lesions accompanied by pain, to major organ disease. When the central nervous system (CNS) is affected, the LCH patient may exhibit signs and symptoms of hypothalamic and pituitary dysfuncti

2-chlorodeoxyadenosine (2-CDA) for the t

2-chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients

✍ Stine, Kimo C.; Saylors, Robert L.; Williams, Laura L.; Becton, David L. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 1 views

Background. Pediatric patients with Langerhans cell histiocytosis (LCH) may become refractory to conventional therapy or present with repeated recurrences over several years. Current therapeutic options such as prednisone, vinblastine, etoposide, and cyclosporine are associated with significant acut

Secondary acute promyelocytic leukemia a

Secondary acute promyelocytic leukemia after treatment with etoposide for langerhans cell histiocytosis (LCH)

✍ Lopes, Luiz Fernando; de Camargo, Beatriz 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 24 KB 👁 2 views

To the Editor: We here describe a 3-year-old-boy who was treated for LCH using vinblastine, etoposide and prednisone according to the International Langerhans Cell Histiocytosis Study I. The patient was admitted in March 1993 with multiple bone lesions, diabetes insipidus and biopsy confirmed LCH. H

Langerhans cell histiocytosis in childre

Langerhans cell histiocytosis in children: does soluble interleukin-2-receptor correlate with both disease extent and activity?

✍ Schultz, Christian; Klouche, Mariam; Friedrichsdorf, Stefan; Richter, Nina; Kroe 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

Background. Langerhans cell histiocytosis (LCH) is characterized by monoclonal proliferation of activated Langerhans cells. Neither etiology nor pathomechanism of this disorder is presently known. However, despite monoclonality LCH might represent a reactive clonal disorder induced by immune dysfunc

Treatment of refractory large granular l

Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine

✍ Edelman, Martin J.; O'Donnell, Robert T.; Meadows, Ivan 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

A 50-year-old man with large granular lymphocytic leukemia (CD3+, CD8+) complicated by severe pancytopenia and life-threatening infections refractory to therapy with prednisone, methotrexate, cyclosporine, and G-CSF is described. Treatment with two cycles of 2-chlorodeoxyadenosine (2-CDA) at 0.1 mg/

Risk of secondary leukemia after treatme

Risk of secondary leukemia after treatment with etoposide VP-16) for Langerhans cell histiocytosis in Italian and Austrian-German populations

✍ Riccardo Haupt; Thomas R. Fears; Ansgar Heise; Helmut Gadner; Giuseppe Loiacono; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 49 KB 👁 2 views

To estimate the risk of secondary leukemias after treatment with etoposide (VP-16), we evaluated subjects treated for Langerhans' cell histiocytosis (LCH) according to cooperative protocols in Italy or in Austria, Germany, Holland and Switzerland (AGDS). For each subject, information was collected o